Submitted for Publication: January 10, 2014; final revision received July 14, 2014; accepted August 20, 2014.
Published Online: February 25, 2015. doi:10.1001/jamapsychiatry.2014.2170.
Study concept and design: Versace, Almeida, Travis, Kowatch, Birmaher, Axelson, Frazier, Youngstrom, Findling, Phillips.
Acquisition, analysis, or interpretation of data: Versace, Acuff, Bertocci, Bebko, Almeida, Perlman, Leemans, Schirda, Aslam, Dwojak, Bonar, Travis, Gill, Demeter, Diwadkar, Sunshine, Holland, Kowatch, Birmaher, Horwitz, Arnold, Fristad, Findling.
Drafting of the manuscript: Versace, Bertocci, Almeida, Birmaher, Phillips.
Critical revision of the manuscript for important intellectual content: Versace, Acuff, Bertocci, Bebko, Almeida, Perlman, Leemans, Schirda, Aslam, Dwojak, Bonar, Travis, Gill, Demeter, Diwadkar, Sunshine, Holland, Axelson, Horwitz, Frazier, Arnold, Fristad, Youngstrom, Phillips.
Statistical analysis: Versace, Acuff, Almeida, Diwadkar, Phillips.
Obtained funding: Perlman, Demeter, Diwadkar, Holland, Kowatch, Birmaher, Horwitz, Fristad, Findling, Phillips.
Administrative, technical, or material support: Almeida, Leemans, Schirda, Aslam, Dwojak, Bonar, Travis, Gill, Sunshine, Birmaher, Axelson, Horwitz, Frazier, Findling, Phillips.
Study supervision: Perlman, Sunshine, Kowatch, Birmaher, Axelson, Findling, Phillips.
Conflict of Interest Disclosures: Dr Sunshine receives or has received research support from Siemens Healthcare and Case Center for Imaging Research. Dr Frazier has received federal funding or research support from, acted as a consultant to, received travel support from, and/or received a speaker’s honorarium from Bristol-Myers Squibb, Brain and Behavior Research, Forest Laboratories, Ingalls Foundation, IntegraGen, National Institutes of Health, Shire Development, and Simons Foundation. Dr Arnold has received research funding from CureMark, Forest, Lilly, and Shire; advisory board honoraria from Biomarin, Novartis, Noven, Otsuka, Roche, Seaside Therapeutics, and Shire; consulting fees from Gowlings, Pfizer, and Tris Pharma; and travel support from Noven. Dr Findling receives or has received research support, acted as a consultant for, and/or served on a speakers bureau for Alexza Pharmaceuticals, American Psychiatric Press, AstraZeneca, Bracket, Bristol-Myers Squibb, Clinsys, Cognition Group, Dana Foundation, Eli Lilly and Company, Forest, GlaxoSmithKline, Guilford Press, Johns Hopkins University Press, Johnson & Johnson, KemPharm, Lundbeck, Merck, National Institutes of Health, Novartis, Noven, Otsuka, Oxford University Press, Pfizer, Physicians Postgraduate Press, Rhodes Pharmaceuticals, Roche, Sage, Seaside Pharmaceuticals, Shire, Stanley Medical Research Institute, Sunovion, Supernus Pharmaceuticals, Transcept Pharmaceuticals, Validus, and WebMD. No other disclosures are reported.
Funding/Support: The study was supported by National Institute of Mental Health grants 2R01 MH73953-06A1 (Drs Birmaher and Phillips), 2R01 MH73816-06A1 (Dr Holland), 2R01 MH73967-06A1 (Dr Findling), and 2R01 MH73801-06A1 (Dr Fristad); National Institute of General Medical Sciences grant T32GM008208 (Ms Acuff, Medical Scientist Training Program student); and by the Netherlands Organization for Scientific Research VIDI grant 639.072.411 (Dr Leemans).
Role of the Funder/Sponsor: The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Correction: This article was corrected on March 5, 2015, to fix the Funding/Support section.